sebastiano mercadante

Prof. sebastiano mercadante

La Maddalena
+1
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JPJudith A. Paice
Judith A. Paice
KBKari Bohlke
Kari Bohlke
DBDebra Barton
Debra Barton
DCDavid S. Craig
David S. Craig
AEAreej El-Jawahri
Areej El-Jawahri
Eduardo BrueraEduardo Bruera
Eduardo Bruera
PURPOSE: To provide guidance on the use of opioids to manage pain from cancer or cancer treatment in adults. METHODS: A systematic review of the literature identified systematic reviews and randomized controlled trials of the efficacy and safety of opioid analgesics in people with cancer, approaches to opioid initiation and titration, and the prevention and management of opioid adverse events. PubMed and the Cochrane Library were searched from January 1, 2010, to February 17, 2022. American Society of Clinical Oncology convened an Expert Panel to review the evidence and formulate recommendations. RESULTS: The evidence base consisted of 31 systematic reviews and 16 randomized controlled trials. Opioids have primarily been evaluated in patients with moderate-to-severe cancer pain, and they effectively reduce pain in this population, with well-characterized adverse effects. Evidence was limited for several of the questions of interest, and the Expert Panel relied on consensus for these recommendations or noted that no recommendation could be made at this time. RECOMMENDATIONS: Opioids should be offered to patients with moderate-to-severe pain related to cancer or active cancer treatment unless contraindicated. Opioids should be initiated PRN (as needed) at the lowest possible dose to achieve acceptable analgesia and patient goals, with early assessment and frequent titration. For patients with a substance use disorder, clinicians should collaborate with a palliative care, pain, and/or substance use disorder specialist to determine the optimal approach to pain management. Opioid adverse effects should be monitored, and strategies are provided for prevention and management. Additional information is available at www.asco.org/supportive-care-guidelines .

1 October 2019 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
sebastiano mercadantesebastiano mercadante
sebastiano mercadante
EAEdoardo Arcuri
Edoardo Arcuri
ASAngela Santoni
Angela Santoni

31 January 2002 in Cancer
Verified
Journal Article
Closed access
PDF file
sebastiano mercadantesebastiano mercadante
sebastiano mercadante
LRLukas Radbruch
Lukas Radbruch
ACAugusto Caraceni
Augusto Caraceni
NCNathan Cherny
Nathan Cherny
SKStein Kaasa
Stein Kaasa
SNSteering Committee of the European Association for Palliative Care (EAPC) Research Network
Steering Committee of the European Association for Palliative Care (EAPC) Research Network

16 August 2018 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
sebastiano mercadantesebastiano mercadante
sebastiano mercadante
Cesare GregorettiCesare Gregoretti
Cesare Gregoretti
Andrea CortegianiAndrea Cortegiani
Andrea Cortegiani
Palliative care is patient and family-centered care that optimizes quality of life by anticipating, preventing, and treating suffering when “curative” therapies are futile. In the Intensive Care Unit (ICU), critically ill patients receive life-sustaining therapies with the goal of restoring or maintaining organ function. Palliative Care in the ICU is a widely discussed topic and it is increasingly applied in clinics. It encompasses symptoms control and end-of-life management, communication with relatives and setting goals of care ensuring dignity in death and decision-making power. However, effective application of Palliative Care in ICU presupposes specific knowledge and training which anesthesiologists and critical care physicians may lack. Moreover, logistic issues such protocols for patients’ selection, application models and triggers for consultation of external experts are still matter of debate. The aim of this review is to provide the anesthesiologists and intensivists an overview of the aims, current evidence and practical advices about the application of palliative care in ICU.

1 June 2006 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
sebastiano mercadantesebastiano mercadante
sebastiano mercadante
EBEduardo Bruera
Eduardo Bruera

1 June 2001 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
sebastiano mercadantesebastiano mercadante
sebastiano mercadante
Alessandra CasuccioAlessandra Casuccio
Alessandra Casuccio
FFFabio Fulfaro
Fabio Fulfaro
LGLiliana Groff
Liliana Groff
RBRoberto Boffi
Roberto Boffi
CRCarla Ripamonti
Carla Ripamonti
PURPOSE: To evaluate the clinical benefits of switching from morphine to oral methadone in patients who experience poor analgesia or adverse effects from morphine. PATIENTS AND METHODS: Fifty-two consecutive cancer patients receiving oral morphine but with uncontrolled pain and/or moderate to severe opioid adverse effects were switched to oral methadone administered every 8 hours using different dose ratios. Intensity of pain and adverse effects were assessed daily, and the symptom distress score (DS) was calculated before and after switching. RESULTS: Data were analyzed for 50 patients. Switching was considered effective in 80% of the patients; results were achieved in an average of 3.65 days. In the 10 patients who switched to methadone because of uncontrolled pain, a significant reduction in pain intensity (P < .005) and an average of a 33% increase in methadone doses necessary (P < .01) were found after an average of 3.5 days. DS significantly decreased from an average of 8.4 to 4.5 (P < .0005). In the 32 patients switching because of uncontrolled pain and morphine-related adverse effects, significant improvement was found in pain intensity (P < .0005), nausea and vomiting (P < .03), constipation (P < .001), and drowsiness (P < .01), but a significant increase in the methadone dose of an average of 20% (P < .004) was required. CONCLUSION: In most patients with cancer pain referred for poor pain control and/or adverse effects, switching to oral methadone is a valid therapeutic option. In the clinical setting of poor pain control, higher doses of methadone are necessary with respect to the equianalgesic calculated dose ratios previously published.